Previous 10 | Next 10 |
MeiraGTx (MGTX): Q3 GAAP EPS of -$0.17 beats by $0.52.Revenue of $5.1M (+42.5% Y/Y) beats by $4.19M.Press Release For further details see: MeiraGTx EPS beats by $0.52, beats on revenue
MeiraGTx preparing to initiate Phase 3 trial of AAV-RPGR Plasmid production facility expected to be completed year-end 2020 LONDON and NEW YORK,, Nov. 05, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrate...
LONDON and NEW YORK, Oct. 28, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that twelve-month results from the ongoing Phase 1/2 clinical trial ( NCT03252847 ) of AAV-RPGR,...
Johnson & Johnson (JNJ) unit, Janssen Pharmaceuticals and licensor MeiraGTx Holdings (MGTX) announce nine-month data from the ongoing Phase 1/2 clinical trial of AAV-RPGR, an investigational gene therapy in development for the treatment of patients with X-linked retinitis pigmentosa ...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week ahead Investors head into next week with a few October surprises already in the books. Stimulus drama and further developments...
Data presented a t EURETINA 2020 Virtual Congress show sustained improvements in retinal sensitivity at nine months S ignificant improvement s were also demonstrated in the time taken to walk through a vision-...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
LONDON and NEW YORK, Sept. 28, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., president and chief executive officer, will present at the Chardan 4 th...
LONDON and NEW YORK, Sept. 22, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced nine-month results from the ongoing Phase 1/2 clinical trial ( NCT03252847 ) of AAV-RPGR, an in...
Company Overview MeiraGTx ( MGTX ) is a clinical-stage gene therapy company targeting serious conditions with no existing curative options or even acceptable therapeutic approaches. It has four clinical-stage programs for ocular conditions, one for Parkinson's disease, and one for radiatio...
News, Short Squeeze, Breakout and More Instantly...
MeiraGTx Holdings plc Company Name:
MGTX Stock Symbol:
NASDAQ Market:
MeiraGTx Holdings plc Website:
- Positive data from the Phase 1 AQUAx study in radiation-induced xerostomia (RIX) presented in an oral session at the American Academy of Oral Medicine 2024 annual meeting (AAOM) April 17-20, 2024 - Received $50 million milestone following initiation of the extension study for the Ph...
LONDON and NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced the Company gave an oral presentation at the American Academy of Oral Medicine Annual Conference, being held f...
2024-04-17 00:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...